

QIBA FDG-PET Biomarker Committee (BC) Call

06 April 2018 at 9 AM CT

Call Summary

In attendance:

Rathan Subramaniam, MD, PhD, MPH (Co-Chair)

Scott Wollenweber, PhD (Co-Chair)

Cris Crisman, MBA

Howard Higley, PhD

Adriaan Lammertsma, PhD

Martin Lodge, PhD

Alan Maurer, MD

P. David Mozley, MD

Jayant Narang, MD

Nancy Obuchowski, PhD

Amy Perkins, PhD

Eric Perlman, MD

Fabien Ricard, MD, MS

Mitsuaki Tatsumi, MD

RSNA

Joe Koudelik

Julie Lisiecki

Moderator: Dr. Wollenweber

Status of Recruitment for PET/MRI Task Force

- 55 people are currently signed up for the PET/MRI Task Force (TF) to modify the existing QIBA FDG-PET/CT Profile
- Plans for this task force will be discussed at the upcoming QIBA face-to-face meeting in May
- Dr. Sunderland will draft an email to volunteers for the PET-MRI TF to update them on plans

Round-5 Funded Projects Wrap Up (Dr. Subramaniam)

- Dr. Subramaniam presented an overview of his Round-5 project: Biologic and Reader Repeatability of FDG and CT Volumetric Parameters (ACRIN 6678 & MERCK)
- More patient data would be helpful for additional scanner types
- Dr. Subramaniam will work independently post-award to complete his work with additional metrics in order to determine what other factors are contributing to the variability
- A manuscript will be submitted to *JNM* once additional scanner data has been compiled later this year

Claim Confirmed Clinical Trial Efforts (Dr. Subramaniam)

- The application for ACR Foundation funding (\$275, 000) was submitted on February 25th for 125 subjects at different locations, to include funding for the scans and statistical oversight by Dr. Obuchowski and support for 3 readers
- While the BC waits to hear back from ACR, efforts to refine the imaging protocol continue
- Leadership changes at ACR have moved the timetable for a decision from May to June at the earliest
- An additional proposal was presented to the [Imaging Core Laboratory Group](#) of the ECOG-ACRIN Cancer Research Group
- If this proposal is approved by the *Experimental Imaging Sciences Committee*, it will be brought before leadership at the [ECOG-ACRIN meeting in May](#)
- If approved, the trial would be considered a formal NCI trial
- If approved, formal support would be requested from the top five disease sites by Drs. Kinahan and Subramaniam in the areas of head and neck, breast, lung, colorectal, and gastrointestinal cancers
- In testing the Profile claim, the goal is to be as broad as possible but not to overstep what the claim can support

FDA Biomarker Qualification Effort Update (Dr. Higley)

- Dr. Higley indicated that there have been some changes to the FDA biomarker qualification efforts
- A summary / update regarding any recent developments for FDG-PET and CT Volumetry is needed for FDA review
- Dr. Higley will keep the respective QIBA biomarker committee co-chairs apprised of developments

Planning for the 2018 QIBA Annual Meeting:

- All members will be prompted on the next call (5/4) for topic suggestions for breakout session discussions

Action Items for Next Call:

- Dr. Kinahan to circulate updated proposed paper for *Radiology* for review and comment by the BC co-chairs
- Dr. Sunderland to invite Dr. LaForest to lead the PET-MRI Profile TF
- The next call will focus on more in-depth study design for the ECOG-ACRIN hosted clinical trial

Nuclear Medicine WebEx Schedule:

04/13 PET Amyloid BC

04/20 I-123 Profile Writing TF

04/27 NM Leadership - TBD

SPECT TF call:

04/10 TC^{99m} Profile TF @ 2pm CT

05/04 FDG-PET BC

05/11 PET Amyloid BC

05/18 I-123 Profile Writing TF - TBD

05/25 NM Leadership - TBD

SPECT TF call:

05/08 TC^{99m} Profile TF @ 2pm CT

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries.